Table 1.

Characteristics of included publications.

Study ID	Country	Name	Company	Study Type	Vaccine Type	Dose	Day *	Efficacy Against (%)			Ref
								Infection	Hospitalization	Severe/Death
Bernal et al.	England	ChAdOx1 nCoV-19	AstraZeneca	case– control	Adeno vector	1	21	30.00	NA	NA	[25]
Nasreen et al.	Canada	ChAdOx1 nCoV-19	AstraZeneca	case– control	Adeno vector	1	14	67.00	NA	NA	[25]
Pouwels et al.	England	ChAdOx1 nCoV-19	AstraZeneca	case– control	Adeno vector	1	21	46.00	NA	NA	[26]
Xiao-Ning Li	China	CoronaVac	Sinovac Biotech	case– control	Inactivated	1	14	13.80	NA	NA	[27]
Nasreen et al.	Canada	mRNA-1273	Moderna	case– control	mRNA	1	14	72.00	NA	NA	[25]
Ben Y. Reis	NA	BNT162b2	Pfizer- BioNTech	case– control	mRNA	1	14–20	59.00	NA	NA	[28]
Ben Y. Reis	NA	BNT162b2	Pfizer- BioNTech	case– control	mRNA	1	21–27	66.00	NA	NA	[28]
Bernal et al.	England	BNT162b2	Pfizer- BioNTech	case– control	mRNA	1	21–56	35.60	NA	NA	[25]
Nasreen et al.	Canada	BNT162b2	Pfizer- BioNTech	case– control	mRNA	1	14	56.00	NA	NA	[25]
Pouwels et al.	England	BNT162b2	Pfizer- BioNTech	case– control	mRNA	1	21	57.00	NA	NA	[26]
Bernal et al.	England	ChAdOx1 nCoV-19	AstraZeneca	case– control	Adeno vector	2	14	67	NA	NA	[25]
Pouwels et al.	England	AdOx1 nCoV-19	AstraZeneca	case– control	Adeno vector	2	14	71	NA	NA	[26]
Pouwels et al.	England	ChAdOx1 nCoV-19	AstraZeneca	case– control	Adeno vector	2	>14	67	NA	NA	[26]
Sheikh et al.	Scotland	AdOx1 nCoV-19	AstraZeneca	cohort	Adeno vector	2	>14	91	NA	91	[29]
Paul M McKeigue	Scotland	AdOx1 nCoV-19	AstraZeneca	case– control	Live	2	>14	91	88	NA	[30]
Raches Ella	India	BBV152	Bharat Biotech	clinical trial III	Inactivated	2	14	65.2	NA	NA	[31]
xiao-Ning Li	China	CoronaVac	Sinovac Biotech	case– control	Inactivated	2	14	59	NA	NA	[27]
Nasreen et al.	Canada	mRNA-1273	Moderna	case– control	mRNA	2	14	72	NA	NA	[25]
Russell S	NA	mRNA-1273	Moderna	case– control	mRNA	2	28	74	NA	NA	[32]
Tenforde	NA	mRNA-1273	Moderna	case– control	mRNA	2	91–168	86	NA	NA	[33]
Paul M McKeigue	Scotland	BNT162b2/mRNA-1273	Pfizer/Moderna **	case– control	mRNA	2	>14	92	91	NA	[30]
Po Ying Chia	Singapore	BNT162b2/mRNA-1273	Pfizer/ Moderna *	cohort	mRNA	2	>14	96	NA	NA	[34]
Lindsay T. Keegan	USA	BNT162b2/mRNA-1273/Ad26.COV2.S	Pfizer/ Moderna/ J&J ***		mRNA/ adeno vector	2	>14	82	NA	NA	[35]
Russell S	NA	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	28	73	NA	NA	[32]
Tenforde	NA	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	14–84	86	NA	NA	[33]
Ben Y. Reis	NA	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	7–21	88	NA	NA	[28]
Sara Y. Tartof	USA	BNT162b2	Pfizer- BioNTech	cohort	mRNA	2	7	93	93	NA	[36]
Sara Y. Tartof	USA	BNT162b2	Pfizer- BioNTech	cohort	mRNA	2	120	53	NA	NA	[36]
Bernal et al.	England	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	14	88	NA	NA	[25]
Nasreen et al.	Canada	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	7	87	NA	NA	[25]
Pouwels et al.	England	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	0–13	82	NA	NA	[26]
Pouwels et al.	England	BNT162b2	Pfizer- BioNTech	case– control	mRNA	2	>14	80	NA	NA	[26]
Sheikh et al.	Scotland	BNT162b2	Pfizer- BioNTech	cohort	mRNA	2	>14	90.00	NA	90.00	[29]
Xinhua Chen	NA	mRNA-1273	Moderna	cohort	mRNA	3	14–30	97.00	NA	98.30	[18]
Xinhua Chen	NA	BNT162b2	Pfizer- BioNTech	cohort	mRNA	3	14–30	97.20	NA	98.90	[18]
Xinhua Chen	NA	CoronaVac	Sinovac Biotech	cohort	Inactivated	3	60	63.80	NA	75.30	[18]

ChAdOx1: chimpanzee (Ch) adenovirus-vectored vaccine; BNT162b2: BioNTech; J&J: Johnson & Johnson; Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) NA: not available. * Reported vaccine efficacy after vaccination; ** reported for mRNA vaccines (Pfizer/Moderna); *** total of 52.9% with Pfizer, 38.1% with Moderna, and 9.05% with Janssen (Pfizer/Moderna/J&J).